Director/PDMR Shareholding

GlaxoSmithKline PLC
13 February 2007


   Notification of Transactions of Directors, Persons Discharging Managerial
                      Responsibility or Connected Persons


I give below details of changes in interests in the Ordinary shares and American
Depositary Shares (ADSs) of GlaxoSmithKline plc in respect of the
under-mentioned Directors and Persons Discharging Managerial Responsibility:-
                    
Dr J-P Garnier      Sale of 17,411 Ordinary Share ADRs on 13 February 2007 at a 
                    price of $57.37 per ADR. Following this transaction Dr 
                    Garnier's total shareholding in the Company remains 
                    equivalent to more than 17 times his annual basic salary.

Mr R Bondy          Exercise on 13 February 2007 of 3,620 SmithKline Beecham UK 
                    Senior Executive Bonus Investment Rights granted on 20 March 
                    2000 under the SmithKline Beecham Bonus Investment Plan. 
                    Sale of 1,466 shares at a price of £14.65 per share.  Mr 
                    Bondy is retaining the 2,154 remaining shares resulting from 
                    this exercise.


The Company was advised of these transactions on 13 February 2007.

Mr J Clarke         Exercise of nil-price options on 12 February 2007 over 8,103 
                    Ordinary shares granted on 13 February 2003 under the 
                    SmithKline Beecham Mid-Term Incentive Plan ("the MTIP"), 
                    resulting from the deferral of an award made under the
                    MTIP on 24 November 1999.

                    Sale of 3,323 Ordinary shares at a price of £14.63 per 
                    share.  Mr Clarke is retaining the 4,780 remaining shares 
                    resulting from this exercise.

The Company was advised of these transactions on 12 February 2007.

This notification is in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R
(1)(b).


S M Bicknell
Company Secretary

13 February 2007



                      This information is provided by RNS
            The company news service from the London Stock Exchange